rmdopen.bmj6d
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial
Objectives The objectives of this study are to identify a therapeutic serum level for adalimumab associated with remission and low disease activity in patients with rheumatoid arthritis. Methods ...
rmdopen.bmj7d
Is rheumatoid arthritis always preceded by a symptomatic at-risk phase of arthralgia?
Objectives Secondary prevention of rheumatoid arthritis (RA) is generally considered potentially impactful because the entire ...
rmdopen.bmj8d
Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort
Objectives To investigate the occurrence of sick leave (SL) and the impact of clinical and socioeconomic factors on SL in early axial spondyloarthritis (axSpA). Methods Patients with a clinical ...
rmdopen.bmj10d
Three cases of IgG4-RD complicated by splenic artery aneurysm: a complication of IgG4-RD?
Immunoglobulin 4-related disease (IgG4-RD) is known for its potential to affect nearly every organ, particularly a preference for large and middle-sized arteries when vascular involvement occurs.
rmdopen.bmj12d
Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease
3 Interdepartmental Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Rheumatology Unit, Policlinico Le Scotte, University of Siena, Siena, Italy Blau syndrome (BS) and early-onset ...
rmdopen.bmj18d
Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment
Background Approximately 30% of patients with the systemic autoimmune/inflammatory disorder systemic lupus erythematosus (SLE) develop lupus nephritis (LN) that affects treatment and prognosis. Easily ...
rmdopen.bmj26d
Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise – a review
Psoriatic arthritis (PsA) is a complex, multiform and chronic inflammatory disease characterised by the association of arthritis and psoriasis combined with other related conditions and comorbidities.
rmdopen.bmj1mon
Implementation and role of modern musculoskeletal imaging in rheumatological practice in member countries of EULAR
Objectives To document the current training, implementation and role of modern musculoskeletal imaging techniques: ultrasound, magnetic resonance imaging, computed tomography and positron emission ...
rmdopen.bmj1mon
Cardiovascular risk according to genetic predisposition to gout, lifestyle and metabolic health across prospective European and Korean cohorts
Objective Recent studies have reported that gout is associated with a risk of cardiovascular disease (CVD) later in life. However, the predictive value of genetic predisposition to gout combined with ...
rmdopen.bmj1mon
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
Objective To report the efficacy, patient-reported, radiographic and safety outcomes of 4 years’ certolizumab pegol (CZP) treatment in patients with psoriatic arthritis (PsA). Methods RAPID-PsA ...
rmdopen.bmj1mon
SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome
Objectives To evaluate the interferon (IFN) biomarkers sialic acid binding Ig like lectin 1 (SIGLEC1, CD169) and IFN-γ-inducible protein-10 (IP-10) in patients with primary Sjögren's syndrome (pSS).